Moderna (MRNA) Tax Provisions (2018 - 2026)

Moderna (MRNA) has reported Tax Provisions for 9 consecutive years, with $15.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions rose 114.29% year-over-year to $15.0 million in Q2 2026; TTM through Jun 2026 was $64.0 million, a 252.38% increase from a year earlier, with the FY2025 full-year figure at $54.0 million, up 217.39% from the prior year.
• Tax Provisions was $15.0 million for Q2 2026 at Moderna, up from $9.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $1.7 billion in Q3 2023 and troughed at -$384.0 million in Q1 2023.
• A 5-year average of $118.6 million and a median of $10.0 million in 2024 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions jumped 1366.67% in 2022 and sank 233.21% in 2023, its largest moves.
• Over 5 years, Tax Provisions stood at $190.0 million in 2022, then sank by 177.37% to -$147.0 million in 2023, then soared by 56.46% to -$64.0 million in 2024, then soared by 142.19% to $27.0 million in 2025, then sank by 44.44% to $15.0 million in 2026.
• The last three Tax Provisions figures came in at $15.0 million (Q2 2026), $9.0 million (Q1 2026), and $27.0 million (Q4 2025), per Business Quant data.